Overview

• Pfizer confirmed a deal to lower prices on some medicines in the U.S. and pledged a $70 billion expansion of domestic manufacturing.
• Trump unveiled TrumpRx, a government-promoted portal set to launch in early 2026 that displays negotiated prices and redirects users to manufacturers’ direct-sale channels.
• Pfizer will receive a three-year exemption from a planned 100% tariff on branded drug imports as part of the agreement, while broader tariff threats continue to pressure the industry.
• The administration says Medicaid purchases will use Most Favored Nation pricing, though officials have not specified which drugs are covered or how insured patients’ costs will change.
• Drugmakers and PhRMA warn of harm to innovation, and experts note similar MFN efforts were blocked by courts, while some companies have raised prices abroad in response.